Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
A systematic review of bevacizumab efficacy in breast cancer
Iben Kümler, Ole Grummedal Christiansen,
Dorte Lisbet Nielsen
Department of Clinical Medicine
50
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A systematic review of bevacizumab efficacy in breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Bevacizumab
100%
Breast Cancer
100%
Phase II Trial
80%
Response Rate
60%
Neoadjuvant Setting
60%
Phase II Study
40%
Progression-free Survival
40%
Metastatic Setting
40%
Angiogenesis Inhibition
20%
Cancer Metastasis
20%
Cancer Invasion
20%
Molecular Biomarkers
20%
Literature Search
20%
Cancer Growth
20%
Survival Benefit
20%
Breast Cancer Treatment
20%
Computer-based
20%
Predictive Biomarker
20%
PubMed
20%
Phase II Clinical Trial
20%
Phase III Clinical Trial
20%
Bevacizumab Treatment
20%
Overall Survival
20%
Time to Progression
20%
Angiogenesis
20%
Cancer Treatment
20%
Molecular Mechanism
20%
Medicine and Dentistry
Bevacizumab
100%
Systematic Review
100%
Breast Cancer
100%
Biological Marker
33%
Progression Free Survival
33%
Metastatic Carcinoma
16%
Angiogenesis
16%
Antiangiogenic Activity
16%
Phase II Trials
16%
Overall Survival
16%
Tumor Invasion
16%
Clinical Trial
16%
Cancer Growth
16%
Cancer Treatment
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Breast Cancer
100%
Progression Free Survival
33%
Biological Marker
33%
Tumor Invasion
16%
Phase II Trials
16%
Cancer Growth
16%
Malignant Neoplasm
16%
Overall Survival
16%
Clinical Trial
16%
Metastasis
16%
Nursing and Health Professions
Breast Cancer
100%
Systematic Review
100%
Biological Marker
33%
Progression Free Survival
33%
Overall Survival
16%
Tumor Invasion
16%
Cancer Growth
16%
Malignant Neoplasm
16%
Metastasis
16%